Peter Wehrwein has been the lead editor of Managed Healthcare Executive since February 2020.
Geoffrey G. Emerson of Retina Consultants of Minnesota and medical director at the Phillips Eye Institute in Minneapolis and an associate adjunct professor at the University of Minnesota, previews the 2024 annual meeting of the American Society of Retina Specialists (ASRS) starting Wednesday, July 17, in Stockholm, Sweden.
One theme of the Federal Trade Commission’s interim take on pharmacy benefit managers is vertical integration and how that affects competition in the industry.
The active ingredient in Ozempic and Wegovy is linked to nonarteritic anterior ischemic optic neuropathy (NAION), the second most common form of optic neuropathy. This is apparently the first study to link semaglutide to the eye condition.
The presidential candidates didn't spend a lot of time talking about healthcare issues last night, but Democrats are concerned about Biden's performance, especially early on.
Lack of standardization has obscured complication rates in clinical trials, say a team of researchers. In results reported in the journal Ophthalmology earlier month, they list 67 ocular complications that experts agreed upon using a Delphi process,
The CMS released its projections earlier this month, saying healthcare spending will hit $7.7 trillion by 2032.
The newspaper’s investigation, which included interviewing 300 peole, found that pharmacy benefit manager often act in their own financial interest by overcharging employers and government programs.
Experts on AI spoke about strategies and tactics for implementing artificial intelligence that would assuage worries and build trust during a keynote session at AHIP annual meeting.
Researchers say their findings of increased prevalence argue for screening for diabetic retinopathy in young adults.
Congressional Budget Office analysts say that Medicaid unwinding, immigration and scheduled end of ACA premium subsidies are factors in the increase.
Even though value-based care has been talked about for a long time, it may not be the end.
In 2024, there have been two common health plan issues brought up by employers.
Harvard researcher Zirui Song says research findings show that nospitals higher prices and lower quality.
Three speakers, three different takes on the state of U.S. healthcare and what ails it.
In an interview prior to the AHIP 2024 conference in Las Vegas, MHE spoke with Sachin H. Jain, M.D.,MBA, CEO, SCAN Group and SCAN Health Plan, who acknowledged that while SCAN isn't perfect, they are ahead in simplifying healthcare by recognizing their role in the problem.
In an interview prior to the AHIP 2024 conference in Las Vegas, MHE spoke with Sachin H. Jain, M.D.,MBA, CEO, SCAN Group and SCAN Health Plan, about the need to reimagine U.S. healthcare, emphasizing a leadership crisis.
CDC Director Mandy K. Cohen spabout the agency modernizing data and working with payers and other parts of the healthcare system at the AHIP meeting in Las Vegas.
Merith Basey, executive director of Patients for Affordable Drug, talks about strategies for lowering the cost of new drugs, especially cell and gene therapy, in a second part of a video interview conducted prior to the June 11-13 AHIP 2024 meeting in Las Vegas.
Merith Basey, M.Sc., executive director of Patients for Affordable Drugs, discusses her group's focus on the monopoly pricing of pharmaceutical companies and bills in Congress addressing patent reform and "pay for delay" strategies, in an interview with MHE previewing the presentation she's co-presenting on June 11 at the AHIP 2024 meeting in Las Vegas.
In the latest episode of the Meet the Board podcast series, Managing Editor, Peter Wehrwein, catches up with Chief Clinical Officer at Optum Rx and EAB member, David Calabrese, about his new role alongside his team's progress in improving quality, patient safety and health equity in healthcare.
A growing proportion of small- and medium-sized employers are self-insuring. But with self-insurance, comes fiduciary responsibility and possible scrutiny.
Some large randomized trials have suggested that taking low doses of aspirin on a daily basis would be an easy, inexpensive way of lowering the risk of getting age-related macular degeneration. Not so a well-designed, placebo-controlled study of septuagenarians conducted in Australia.
Researchers find a mismatch between demographics of the neighborhoods where the FQHCs with vision care are located and those using the vision services.
Although bills that would make comprehensive changes to the PBM industry have advanced in Congress, Paul Kelly, a veteran healthcare lobbyist, says a limited version that saves Medicare money may pass as an offsetting "pay for" for extension of more liberal rules for telehealth services that Medicare covers.
A limited pharmacy benefit manager (PBM) reform bill may be used as a "pay for" to offset the costs of extending Medicare telehealth flexibilities, shares Kelly, of Capitol Advocacy & Government Affairs.
Veteran healthcare lobbyist discussed the prospects for the Senate passing comprehensive PBM legislation in the most recent episode of Managed Healthcare's DC Roundtable podcast.
The American Thoracic Society (ATS) has recommended moving to race-neutral equations for assessing what lung functions mean. A study presented at the ATS meeting this weekend projected how the new equation would affect disease classification, lung test standards for becoming a firefighter and VA disability benefits.
Results from a phase 2a study suggest that the benefits of Tezspire (tezepelumab) for people with chronic pulmonary obstructive disease may be limited to those with elevated blood eosinophil counts indicative of type 2 inflammation.
Results from the phase 3 NOTUS trial presented at the ATS meeting confirm benefits of Dupixent (dupilumab) among 20% to 40% of people with chronic obstructive pulmonary disease (COPD) who have evidence of type 2 inflammation.
